日本消化器病学会アーカイブシステム

セッション	検索結果は4件です。 IF4c-4 Successful Therapy with the NS5A Inhibitor Daclatasvir and NS3 Protease Inhibitor Asunaprevir in HCV Genotype 1B-infected Null Responders or Ineligible／Intolerant to PEG-IFN／RBV 　 Background ： Regimens for chronic HCV infection that combine 2 direct－acting antivirals （DAAs）withoutpeginterferon and ribavirin （peg－alfa／RBV）may benefit many infected patients． This study evaluatesd... 第98回日本消化器病学会総会＞ IF4c-5 Host Factors Determining the Efficacy of Hepatitis C Treatment Wan-Long Chuang（Hepatobiliary DivisionDepartment of Internal MedicineKaohsiung Medical University HospitalTaiwan） Combination therapy wi’th pegylated interferon（PEG一工FN）and Ribavirin is the standard of care（SOC）forthe treat血ent chronic． hepatitis C（CHC）．Treating CHC with SOC may reach approxim．ately 50％of sus－tai... 第98回日本消化器病学会総会＞ IF4c-6 Host Factors Determining the Efficacy of Hepatitis C Treatment in Japan Yasuhito Tanaka（Department of Virology & Liver UnitNagoya City University Graduate School of Medical SciencesJapan） The current standard of care （SOC） is combination treatment with pegylated interferon and ribavirin（PEG－IFN／RBV）but this costly and poorly tolerated treatment achieves sustained virological response i... 第98回日本消化器病学会総会＞ IF4c-7 Comprehensive Analysis for Viral Genetic Elements and IL28B Polymorphisms in Response to Peginterferon plus Ribavirin Therapy in HCV-1b Infection Nobuyuki Enomoto（First Department of Internal MedicineUniversity of YamanashiJapan） To comprehensively characterize the contribution of virological factors as well as interleukin 28B （IL28B）single nucleotide polymorphisms （SNPs） in determining treatment responses in pegylated－interfe... 第98回日本消化器病学会総会＞

セッション

検索結果は4件です。

IF4c-4 Successful Therapy with the NS5A Inhibitor Daclatasvir and NS3 Protease Inhibitor Asunaprevir in HCV Genotype 1B-infected Null Responders or Ineligible／Intolerant to PEG-IFN／RBV: 　
Background ： Regimens for chronic HCV infection that combine 2 direct－acting antivirals （DAAs）withoutpeginterferon and ribavirin （peg－alfa／RBV）may benefit many infected patients． This study evaluatesd...
第98回日本消化器病学会総会＞
IF4c-5 Host Factors Determining the Efficacy of Hepatitis C Treatment: Wan-Long Chuang（Hepatobiliary DivisionDepartment of Internal MedicineKaohsiung Medical University HospitalTaiwan）
Combination therapy wi’th pegylated interferon（PEG一工FN）and Ribavirin is the standard of care（SOC）forthe treat血ent chronic． hepatitis C（CHC）．Treating CHC with SOC may reach approxim．ately 50％of sus－tai...
第98回日本消化器病学会総会＞
IF4c-6 Host Factors Determining the Efficacy of Hepatitis C Treatment in Japan: Yasuhito Tanaka（Department of Virology & Liver UnitNagoya City University Graduate School of Medical SciencesJapan）
The current standard of care （SOC） is combination treatment with pegylated interferon and ribavirin（PEG－IFN／RBV）but this costly and poorly tolerated treatment achieves sustained virological response i...
第98回日本消化器病学会総会＞
IF4c-7 Comprehensive Analysis for Viral Genetic Elements and IL28B Polymorphisms in Response to Peginterferon plus Ribavirin Therapy in HCV-1b Infection: Nobuyuki Enomoto（First Department of Internal MedicineUniversity of YamanashiJapan）
To comprehensively characterize the contribution of virological factors as well as interleukin 28B （IL28B）single nucleotide polymorphisms （SNPs） in determining treatment responses in pegylated－interfe...
第98回日本消化器病学会総会＞